Philadelphia, Pennsylvania 19104


Purpose:

This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.


Criteria:

Inclusion Criteria: - males and females - greater than or equal to 2 years and less than or equal to 17 years at enrollment - diagnosis of atopic dermatitis (confirmed by treating physician) - applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks Exclusion Criteria: - past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease - past or present use of oral immunosuppressive therapy


NCT ID:

NCT00568997


Primary Contact:

Valeant Pharmaceuticals
Phone: 908-927-1400


Backup Contact:

Email: johnson.varughese@valent.com
Johnson Varughese
Phone: 908-927-1162


Location Contact:

Philadelphia, Pennsylvania 19104
United States

NA NA

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.